339 related articles for article (PubMed ID: 28106277)
1. Tumor-Targeting Salmonella typhimurium A1-R Sensitizes Melanoma With a BRAF-V600E Mutation to Vemurafenib in a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model.
Kawaguchi K; Igarashi K; Murakami T; Zhao M; Zhang Y; Chmielowski B; Kiyuna T; Nelson SD; Russell TA; Dry SM; Li Y; Unno M; Eilber FC; Hoffman RM
J Cell Biochem; 2017 Aug; 118(8):2314-2319. PubMed ID: 28106277
[TBL] [Abstract][Full Text] [Related]
2. Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model.
Kawaguchi K; Murakami T; Chmielowski B; Igarashi K; Kiyuna T; Unno M; Nelson SD; Russell TA; Dry SM; Li Y; Eilber FC; Hoffman RM
Oncotarget; 2016 Nov; 7(44):71737-71743. PubMed ID: 27690220
[TBL] [Abstract][Full Text] [Related]
3. Salmonella typhimurium A1-R targeting of a chemotherapy-resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib or temozolomide.
Kawaguchi K; Igarashi K; Murakami T; Kiyuna T; Zhao M; Zhang Y; Nelson SD; Russell TA; Dry SM; Singh AS; Chmielowski B; Li Y; Unno M; Eilber FC; Hoffman RM
Cell Cycle; 2017 Jul; 16(13):1288-1294. PubMed ID: 28622068
[TBL] [Abstract][Full Text] [Related]
4. Tumor-targeting Salmonella typhimurium A1-R combined with temozolomide regresses malignant melanoma with a BRAF-V600E mutation in a patient-derived orthotopic xenograft (PDOX) model.
Kawaguchi K; Igarashi K; Murakami T; Chmielowski B; Kiyuna T; Zhao M; Zhang Y; Singh A; Unno M; Nelson SD; Russell TA; Dry SM; Li Y; Eilber FC; Hoffman RM
Oncotarget; 2016 Dec; 7(52):85929-85936. PubMed ID: 27835903
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma.
Kawaguchi K; Higuchi T; Li S; Han Q; Tan Y; Igarashi K; Zhao M; Miyake K; Kiyuna T; Miyake M; Ohshiro H; Sugisawa N; Zhang Z; Razmjooei S; Wangsiricharoen S; Chmielowski B; Nelson SD; Russell TA; Dry SM; Li Y; Eckardt MA; Singh AS; Singh SR; Eilber FC; Unno M; Hoffman RM
Biochem Biophys Res Commun; 2018 Sep; 503(4):3086-3092. PubMed ID: 30166061
[TBL] [Abstract][Full Text] [Related]
6. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
7. A Network Meta-Analysis of Short and Long-Term Efficacy of Targeted Therapy With Single or Double-Drug Regimens in the Treatment of Stage III/IV Malignant Melanoma Based on 16 Randomized Controlled Trials.
Xie T; Huang CY; Kang X; Luo JS; Qin XM; Han F
J Cell Biochem; 2018 Jan; 119(1):640-649. PubMed ID: 28628251
[TBL] [Abstract][Full Text] [Related]
8. High efficacy of tumor-targeting Salmonella typhimurium A1-R on a doxorubicin- and dactolisib-resistant follicular dendritic-cell sarcoma in a patient-derived orthotopic xenograft PDOX nude mouse model.
Kiyuna T; Murakami T; Tome Y; Kawaguchi K; Igarashi K; Zhang Y; Zhao M; Li Y; Bouvet M; Kanaya F; Singh A; Dry S; Eilber FC; Hoffman RM
Oncotarget; 2016 May; 7(22):33046-54. PubMed ID: 27105519
[TBL] [Abstract][Full Text] [Related]
9. A combination of irinotecan/cisplatinum and irinotecan/temozolomide or tumor-targeting Salmonella typhimurium A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model.
Kiyuna T; Tome Y; Murakami T; Miyake K; Igarashi K; Kawaguchi K; Oshiro H; Higuchi T; Miyake M; Sugisawa N; Zhang Z; Razmjooei S; Wangsiricharoen S; Chmielowski B; Nelson SD; Russell TA; Dry SM; Li Y; Eckardt MA; Singh AS; Chawla S; Kanaya F; Eilber FC; Singh SR; Zhao M; Hoffman RM
Biochem Biophys Res Commun; 2018 Nov; 505(3):733-739. PubMed ID: 30292411
[TBL] [Abstract][Full Text] [Related]
10. Recombinant Methioninase Combined With Tumor-targeting
Igarashi K; Kawaguchi K; Zhao M; Han Q; Tan Y; Kiyuna T; Miyake K; Higuchi T; Nelson SD; Dry SM; Li Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Singh SR; Tsuchiya H; Hoffman RM
Anticancer Res; 2020 May; 40(5):2515-2523. PubMed ID: 32366396
[TBL] [Abstract][Full Text] [Related]
11. Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as -positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse models.
Kawaguchi K; Igarashi K; Li S; Han Q; Tan Y; Miyake K; Kiyuna T; Miyake M; Murakami T; Chmielowski B; Nelson SD; Russell TA; Dry SM; Li Y; Unno M; Eilber FC; Hoffman RM
Oncotarget; 2018 Jan; 9(1):915-923. PubMed ID: 29416666
[TBL] [Abstract][Full Text] [Related]
12. Vemurafenib and cobimetinib in BRAF-mutated melanoma.
Rahman A
Lancet Oncol; 2014 Nov; 15(12):e535. PubMed ID: 25602110
[No Abstract] [Full Text] [Related]
13. Tumor-targeting Salmonella typhimurium A1-R overcomes partial carboplatinum-resistance of a cancer of unknown primary (CUP).
Miyake K; Kiyuna T; Miyake M; Zhao M; Wangsiricharoen S; Kawaguchi K; Zhang Z; Higuchi T; Razmjooei S; Li Y; Nelson SD; Russell T; Singh A; Murakami T; Hiroshima Y; Momiyama M; Matsuyama R; Chishima T; Singh SR; Chawla SP; Eilber FC; Endo I; Hoffman RM
Tissue Cell; 2018 Oct; 54():144-149. PubMed ID: 30309504
[TBL] [Abstract][Full Text] [Related]
14. Tumor targeting Salmonella typhimurium A1-R in combination with gemcitabine (GEM) regresses partially GEM-resistant pancreatic cancer patient-derived orthotopic xenograft (PDOX) nude mouse models.
Kawaguchi K; Miyake K; Zhao M; Kiyuna T; Igarashi K; Miyake M; Higuchi T; Oshiro H; Bouvet M; Unno M; Hoffman RM
Cell Cycle; 2018; 17(16):2019-2026. PubMed ID: 29963961
[TBL] [Abstract][Full Text] [Related]
15. Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation.
Mey UJM; Renner C; von Moos R
Hematol Oncol; 2017 Dec; 35(4):890-893. PubMed ID: 27641727
[TBL] [Abstract][Full Text] [Related]
16. Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention.
Kawaguchi K; Han Q; Li S; Tan Y; Igarashi K; Kiyuna T; Miyake K; Miyake M; Chmielowski B; Nelson SD; Russell TA; Dry SM; Li Y; Singh AS; Eckardt MA; Unno M; Eilber FC; Hoffman RM
Cell Cycle; 2018; 17(3):356-361. PubMed ID: 29187018
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Tumor-Targeting Salmonella A1-R on a Melanoma Patient-Derived Orthotopic Xenograft (PDOX) Nude-Mouse Model.
Yamamoto M; Zhao M; Hiroshima Y; Zhang Y; Shurell E; Eilber FC; Bouvet M; Noda M; Hoffman RM
PLoS One; 2016; 11(8):e0160882. PubMed ID: 27500926
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of USP14 enhances anti-tumor effect in vemurafenib-resistant melanoma by regulation of Skp2.
Wu T; Li C; Zhou C; Niu X; Li G; Zhou Y; Gu X; Cui H
Cell Biol Toxicol; 2023 Oct; 39(5):2381-2399. PubMed ID: 35648318
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.
Kundu A; Quirit JG; Khouri MG; Firestone GL
Mol Carcinog; 2017 Jan; 56(1):49-61. PubMed ID: 26878440
[TBL] [Abstract][Full Text] [Related]
20. Tumor-targeting Salmonella typhimurium A1-R arrests a doxorubicin-resistant PDGFRA-amplified patient-derived orthotopic xenograft mouse model of pleomorphic liposarcoma.
Kiyuna T; Tome Y; Murakami T; Zhao M; Miyake K; Igarashi K; Kawaguchi K; Miyake M; Oshiro H; Higuchi T; Li Y; Dry SM; Nelson SD; Russell TA; Eckardt MA; Singh AS; Kanaya F; Eilber FC; Hoffman RM
J Cell Biochem; 2018 Sep; 119(9):7827-7833. PubMed ID: 29932244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
